Mumbai, Nov. 18 -- The approval resulted from a collaboration between Glenmark and Cosmo Pharmaceuticals N.V.

The approval covers the treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with usage in adolescents restricted to facial application. Glenmark will commercialize the product across 15 European countries: Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, and Sweden.

Christoph Stoller, President & Business Head - Europe and Emerging Markets of Glenmark Pharmaceuticals, said, "The approval is a key milestone in executing our mission to become a research-led, global pharmaceutical company. Winlevi is the first N...